RFG
IHE icon

REAP Financial Group’s iShares US Pharmaceuticals ETF IHE Stock Holding History

REAP Financial Group’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-63
Closed -$4.15K – 612
2024
Q4 		$4.15K Hold
63
– – ﹤0.01% 459
2024
Q3 		$4.45K Buy
+63
New +$4.39K ﹤0.01% 464

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

REAP Financial Group's IHE Position: Q1 2025 in Review

REAP Financial Group sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2025, closing a stake of 63 shares — an estimated $4.15K sold.

REAP Financial Group first reported a position in IHE in Q3 2024 and held it in 2 quarters. The position peaked at $4.45K in Q3 2024. 149 funds tracked by Wall St. Rank hold IHE as of Q1 2025.

  • REAP Financial Group reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2025 after selling out during the quarter.
  • REAP Financial Group sold 63 iShares US Pharmaceuticals ETF shares in Q1 2025, an estimated $4.15K.
  • REAP Financial Group first reported a position in iShares US Pharmaceuticals ETF in Q3 2024 and held it in 2 quarters.
  • REAP Financial Group's iShares US Pharmaceuticals ETF position peaked at $4.45K in Q3 2024.
  • 149 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2025.

Based on REAP Financial Group's 13F filing for Q1 2025, filed 14 May 2025.